Global Non-insulin Diabetes Therapeutics Market 2018-2022

  • ID: 4530612
  • Report
  • Region: Global
  • 101 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • AstraZeneca
  • Eli Lilly
  • Merck
  • Novo Nordisk
  • Sanofi
  • MORE
About Non-insulin Diabetes Therapeutics

Non-insulin diabetes therapeutics are mostly administered orally and prescribed when diet and exercise are insufficient to control elevated blood glucose levels.

The analysts forecast the global non-insulin diabetes therapeutics market to grow at a CAGR of 11.37% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the global non-insulin diabetes therapeutics market for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, Global Non-insulin Diabetes Therapeutics Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • AstraZeneca
  • Eli Lilly
  • Merck
  • Novo Nordisk
  • Sanofi
Market drivers
  • Increasing number of people with type 2 diabetes
  • For a full, detailed list, view the full report
Market challenges
  • High barriers to entry
  • For a full, detailed list, view the full report
Market trends
  • Innovations in therapies
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AstraZeneca
  • Eli Lilly
  • Merck
  • Novo Nordisk
  • Sanofi
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 05: MARKET SIZING
  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
  • Bargaining power of suppliers
  • Bargaining power of buyers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 07: MARKET SEGMENTATION BY TYPE
  • Overview
  • Comparison by type
  • DPP4 inhibitor - Market size and forecast 2017-2022
  • GLP-1 agonist - Market size and forecast 2017-2022
  • SGLT2 inhibitor - Market size and forecast 2017-2022
  • Others - Market size and forecast 2017-2022
  • Market opportunity by type
PART 08: CUSTOMER LANDSCAPE

PART 09: REGIONAL LANDSCAPE
  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Key leading countries
  • Market opportunity
PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 12: MARKET TRENDS
  • Innovations in therapies
  • Strategic alliances between vendors
  • Increasing demand for combination drugs
PART 13: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 14: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca
  • Eli Lilly
  • Merck
  • Novo Nordisk
  • Sanofi
PART 15: APPENDIX
  • List of abbreviations
List of Exhibits
Exhibit 01: Parent market
Exhibit 02: Global diabetes therapeutics market: Segments
Exhibit 03: Market characteristics
Exhibit 04: Global non-insulin diabetes therapeutics market: Segments
Exhibit 05: Market definition: Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global non-insulin diabetes therapeutics market 2017-2022 ($ millions)
Exhibit 09: Global non-insulin diabetes therapeutics market: Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Bargaining power of buyers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition: Five forces 2017
Exhibit 18: Segmentation by type: Market share 2017-2022 (%)
Exhibit 19: Comparison by type
Exhibit 20: DPP4 inhibitor 2017-2022 ($ millions)
Exhibit 21: DPP4 inhibitor: Year-over-year growth 2018-2022 (%)
Exhibit 22: GLP-1 agonist 2017-2022 ($ millions)
Exhibit 23: GLP-1 agonist: Year-over-year growth 2018-2022 (%)
Exhibit 24: SGLT2 inhibitor 2017-2022 ($ millions)
Exhibit 25: SGLT2 inhibitor: Year-over-year growth 2018-2022 (%)
Exhibit 26: Others 2017-2022 ($ millions)
Exhibit 27: Others: Year-over-year growth 2018-2022 (%)
Exhibit 28: Market opportunity by type
Exhibit 29: Customer landscape
Exhibit 30: Segmentation by geography: Market share 2017-2022 (%)
Exhibit 31: Regional comparison
Exhibit 32: Americas 2017-2022 ($ millions)
Exhibit 33: Americas: Year-over-year growth 2018-2022 (%)
Exhibit 34: EMEA 2017-2022 ($ millions)
Exhibit 35: EMEA: Year-over-year growth 2018-2022 (%)
Exhibit 36: APAC 2017-2022 ($ millions)
Exhibit 37: APAC: Year-over-year growth 2018-2022 (%)
Exhibit 38: Key leading countries
Exhibit 39: Market opportunity
Exhibit 40: Proportion of people aged 20-79 with diabetes 2015
Exhibit 41: Vendor landscape
Exhibit 42: Landscape disruption
Exhibit 43: Vendors covered
Exhibit 44: Vendor classification
Exhibit 45: Market positioning of vendors
Exhibit 46: AstraZeneca: Overview
Exhibit 47: AstraZeneca: Business segments
Exhibit 48: AstraZeneca: Organizational developments
Exhibit 49: AstraZeneca: Geographic focus
Exhibit 50: AstraZeneca: Key offerings
Exhibit 51: Eli Lilly: Overview
Exhibit 52: Eli Lilly: Business segments
Exhibit 53: Eli Lilly: Organizational developments
Exhibit 54: Eli Lilly: Geographic focus
Exhibit 55: Eli Lilly: Key offerings
Exhibit 56: Merck: Overview
Exhibit 57: Merck: Business segments
Exhibit 58: Merck: Organizational developments
Exhibit 59: Merck: Geographic focus
Exhibit 60: Merck: Key offerings
Exhibit 61: Novo Nordisk: Overview
Exhibit 62: Novo Nordisk: Business segments
Exhibit 63: Novo Nordisk: Organizational developments
Exhibit 64: Novo Nordisk: Geographic focus
Exhibit 65: Novo Nordisk: Key offerings
Exhibit 66: Sanofi: Overview
Exhibit 67: Sanofi: Business segments
Exhibit 68: Sanofi: Organizational developments
Exhibit 69: Sanofi: Geographic focus
Exhibit 70: Sanofi: Key offerings
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AstraZeneca
  • Eli Lilly
  • Merck
  • Novo Nordisk
  • Sanofi
  • MORE
New Report Released: - Global Non-insulin Diabetes Therapeutics Market 2018-2022.

The author of the report recognizes the following companies as the key players in the global non-insulin diabetes therapeutics market: AstraZeneca, Eli Lilly, Merck, Novo Nordisk, and Sanofi.

Commenting on the report, an analyst from the research team said: “One trend in the market is innovations in therapies. The development of innovative therapies will provide traction to the growth of the non-insulin diabetes therapeutics market. Vendors in the type 2 non-insulin therapies market are opting for advanced therapies including incretins-based type 2 diabetes drugs. Incretins are secreted by the GI tract in response to food intake.”

According to the report, one driver in the market is increasing number of people with type 2 diabetes. The body’s ineffective use of the insulin produced renders in the occurrence of type 2 diabetes. Several individuals are suffering from type 2 diabetes globally, due to causes such as excess body weight and physical inactivity.

Further, the report states that one challenge in the market is high barriers to entry. Several stringent regulations have been imposed on non-insulin diabetes therapeutics by organizations such as the USFDA, the ADA and the EASD.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • AstraZeneca
  • Eli Lilly
  • Merck
  • Novo Nordisk
  • Sanofi
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll